An uncertain future for diet drugs

The limited sales of Vivus' prescription weight-loss drug Qsymia since it came to market last year raise questions over the role of prescription drugs in fighting obesity, Andrew Pollack writes. Aside from its unique problems, Qsymia faces obstacles that other weight-loss treatments are likely to have, including safety issues, modest weight loss and a feeling among obese people and doctors that more willpower is the best weapon against excess weight, he writes.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC